Skip to main content
Livermore
Livermore
ZHEN

Viridian Therapeutics, Inc.

VRDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001590750

In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.

Holders of 5% or more of VRDN

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Viridian Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of VRDN
HolderLatest formStakeChangeFirst filedLatest filingFiling
Fairmount Funds Management LLC13D/A14.04%17.2M shares−1.10 ppfrom 15.14%Jan 5, 20219 filingsMay 13, 2026SEC
Bellevue Group AG13G6.60%6.73M sharesNewMay 15, 20261 filingMay 15, 2026SEC
Paradigm Biocapital Advisors LP13G/A6.10%6.72M shares+1.00 ppfrom 5.10%Feb 14, 20227 filingsAug 14, 2026SEC
Kynam Capital Management, LP13G/A5.70%0 shares+4.16 ppfrom 1.54%May 15, 20253 filingsAug 14, 2026SEC
State Street Corp13G5.50%6.12M shares–Jan 24, 20243 filingsAug 7, 2026SEC
Price T Rowe Associates Inc13G5.20%5.75M sharesNewAug 14, 20261 filingAug 14, 2026SEC
Point72 Asset Management, L.P.13G5.00%5.69M shares–Feb 16, 20213 filingsAug 20, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

89 Schedule 13D and 13G filings on Viridian Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on VRDN
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 19, 2022Fairmount Funds Management LLC13D/AOld format–––SEC
Aug 12, 2022Frazier Life Sciences Public Fund, L.P.13G/AOld format–––SEC
May 31, 2022Millennium Management LLC13GOld format–New–SEC
May 19, 2022Commodore Capital LP13GOld format–New–SEC
Feb 14, 2022Venrock Healthcare Capital Partners III, L.P.13G/AOld format–––SEC
Feb 14, 2022Ra Capital Management, L.P.13G/AOld format–––SEC
Feb 14, 2022D. E. Shaw & Co, L.P.13G/AOld format–––SEC
Feb 14, 2022Citadel Advisors LLC13G/AOld format–––SEC
Feb 14, 2022Paradigm Biocapital Advisors LP13GOld format–New–SEC
Feb 14, 2022Logos Global Management LP13G/AOld format–––SEC
Feb 14, 2022Cormorant Asset Management, LP13G/AOld format–––SEC
Feb 14, 2022Biotechnology Value Fund L P13G/AOld format–––SEC
Feb 14, 2022Point72 Asset Management, L.P.13G/AOld format–––SEC
Feb 11, 2022Ally Bridge MedAlpha Master Fund L.P.13G/AOld format–––SEC
Feb 4, 2022Hawkes Bay Master Investors (Cayman) L.P.13G/AOld format–––SEC
Jan 28, 2022Frazier Life Sciences Public Fund, L.P.13G/AOld format–––SEC
Oct 28, 2021Avidity Partners Management LP13GOld format–New–SEC
Oct 14, 2021Venrock Healthcare Capital Partners III, L.P.13GOld format–New–SEC
Oct 8, 2021Wellington Management Group LLP13G/AOld format–––SEC
Sep 30, 2021Vivo Opportunity, LLC13GOld format–New–SEC
Sep 29, 2021TCG Crossover Management, LLC13G/AOld format–––SEC
Sep 29, 2021Logos Global Management LP13G/AOld format–––SEC
Sep 24, 2021TCG Crossover Management, LLC13G/AOld format–––SEC
Sep 24, 2021Deep Track Capital, LP13GOld format–New–SEC
Sep 23, 2021Fairmount Funds Management LLC13D/AOld format–––SEC
Sep 10, 2021TCG Crossover Management, LLC13GOld format–New–SEC
Aug 26, 2021Frazier Life Sciences Public Fund, L.P.13GOld format–New–SEC
Jun 1, 2021D. E. Shaw & Co, L.P.13G/AOld format–––SEC
May 10, 2021D. E. Shaw & Co, L.P.13GOld format–New–SEC
Mar 15, 2021Ra Capital Management, L.P.13G/AOld format–––SEC
Mar 10, 2021Wellington Management Group LLP13GOld format–New–SEC
Feb 19, 2021Hawkes Bay Master Investors (Cayman) L.P.13GOld format–New–SEC
Feb 16, 2021Citadel Advisors LLC13G/AOld format–––SEC
Feb 16, 2021Point72 Asset Management, L.P.13G/AOld format–––SEC
Jan 19, 2021Cormorant Asset Management, LP13GOld format–New–SEC
Jan 11, 202112:07 PM ETXencor Inc13GOld format–New–SEC
Jan 11, 2021Citadel Advisors LLC13GOld format–New–SEC
Jan 7, 2021Ally Bridge MedAlpha Master Fund L.P.13GOld format–New–SEC
Jan 5, 2021Fairmount Funds Management LLC13DOld format–New–SEC

Form 144: proposed insider sales

6 notices from officers, directors and other affiliates planning to sell Viridian Therapeutics, Inc. shares, newest first.

Form 144 notices for VRDN
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Dec 18, 202311:45 AM ETMeisner LaraFormer officer9.38K$198.4KDec 18, 2023Fidelity Brokerage Services LLCSEC
Dec 12, 20234:19 PM ETHumer KristianFormer CFO252.6K$4.33MDec 12, 2023Fidelity Brokerage Services LLCSEC
Dec 7, 20234:22 PM ETHumer KristianFormer officer24.9K$470.9KDec 7, 2023Fidelity Brokerage Services LLCSEC
Dec 1, 20234:04 PM ETMeisner LaraFormer officer3.13K$53.0KDec 1, 2023Fidelity Brokerage Services LLCSEC
Nov 16, 20234:19 PM ETMyers Scott DunsethFormer Officer and Director35.4K$535.1KNov 16, 2023Fidelity Brokerage Services LLCSEC
Jun 2, 20234:26 PM ETMeisner LaraOfficer12.5K$305.5KJun 2, 202310b5-1JefferiesSEC